Thomas Hall, MD
Dermatology · Stillwater, OKNPI 1174578280
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $537,667 of the $633,420 with a category attached, or 84.9%. 32 manufacturers reported payments, led by Lilly USA, LLC at 31.0% of the total. Among dermatology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,331 payments — averaging $475.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$196K
- AbbVie$191K
- Janssen Scientific Affairs, LLC$74K
- Galderma Laboratories, L.p.$61K
- Johnson & Johnson$57K
- Pfizer$35K
- plus $18K from 26 others
What the payments were for
- Consulting fees$15,3062%
- Speaking & faculty fees$537,66785%
- Travel & lodging$54,9369%
- Food & beverage$24,8154%
- Education$6960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 400 | $196,163 |
| AbbVie(2 entities) | 273 | $191,412 |
| Janssen Scientific Affairs, LLC | 70 | $73,728 |
| Galderma Laboratories, L.p. | 64 | $61,360 |
| Johnson & Johnson | 96 | $57,407 |
| Pfizer | 63 | $34,855 |
| UCB, Inc. | 47 | $8,738 |
| Amgen | 4 | $2,275 |
| LEO Pharma Inc. | 30 | $1,771 |
| Novartis | 101 | $1,446 |
| Sun Pharmaceutical Industries Inc. | 38 | $1,131 |
| E.r. Squibb & Sons, L.L.C. | 24 | $524 |
| Regeneron Healthcare Solutions, Inc. | 13 | $326 |
| Sanofi | 13 | $317 |
| Dermavant Sciences, Inc. | 11 | $315 |
| Arcutis Biotherapeutics, Inc. | 14 | $271 |
| Incyte Corporation | 11 | $269 |
| Mayne Pharma Commercial LLC | 13 | $245 |
| Organon | 4 | $164 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 8 | $140 |
| VYNE Pharmaceuticals Inc. | 7 | $102 |
| Dermira, Inc. | 5 | $86 |
| Boehringer Ingelheim | 3 | $61 |
| Genentech USA, Inc. | 4 | $60 |
| DUSA Pharmaceuticals, Inc. | 3 | $60 |
| Strata Skin Sciences, Inc. | 3 | $42 |
| Kerecis Limited | 1 | $36 |
| Aclaris Therapeutics, Inc. | 2 | $33 |
| Prugen, Inc. Pharmaceuticals | 3 | $27 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Celltrion USA Inc. | 1 | $17 |
| Botanix SB Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$633,420 in reported general payments places this provider in the 95th percentile of 114 dermatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 14 | $94,868 |
| Taltz AutoinjectorIxekizumab | 13 | $92,777 |
| OraceaDoxycycline Monohydrate | 11 | $9,536 |
| Metronidazole | 63 | $3,226 |
| Clobetasol Propionate | 89 | $2,695 |
| Triamcinolone Acetonide | 192 | $2,615 |
| Fluocinonide | 60 | $2,191 |
| Desonide | 23 | $1,271 |
| Doxycycline Hyclate | 65 | $809 |
| Clindamycin Phosphate | 22 | $732 |
| Hydrocortisone | 127 | $722 |
| Ketoconazole | 25 | $621 |
| Betamethasone Dipropionate | 24 | $540 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 21 | $471 |
| Imiquimod | 18 | $372 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $2,275 | $94,86814 claims |
| Galderma Laboratories, L.p.Oracea | $61,360 | $9,53611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 114 dermatology providers in Oklahoma.
Other dermatology in Stillwater
- Sara MetcalfStillwater$8K
- Kristyna IyerStillwater$4K
- George MonksTulsa$530K
- Yaohan LamOklahoma City$88K
- Kimberly JerdanOklahoma City$59K
- Mark DawkinsOklahoma City$56K
- Jeff AlexanderTulsa$41K
- Johnathan LedetTulsa$37K
- John AshleyTulsa$24K
- Thomas UriceNorman$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.